Clinical Trials Directory

Trials / Completed

CompletedNCT06715527

Treatment of Women With Hyperandrogenic PCOS With Two Different Ratios of Myo-inositol:D-chiro-inositol: A Comparison

Treatment of Women With Different Phenotype of Polycystic Ovary Syndrome

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
30 (actual)
Sponsor
Lo.Li.Pharma s.r.l · Industry
Sex
Female
Age
18 Years – 45 Years
Healthy volunteers
Not accepted

Summary

In this study, female patients diagnosed with polycystic ovary syndrome (PCOS) will be enrolled. In particular, those with elevated testosterone or with clinical signs of hyperandrogenism, along with menstrual cycle alterations and/or polycystic ovary morphology at ultrasound, will be included in the study. Current treatments for PCOS include insulin sensitizers (such as metformin) and hormonal contraceptives. However, they are not devoid of side effects or may not be well tolerated, often leading to therapy discontinuation. Inositol represents a valid alternative to standard treatments, as it serves both as insulin sensitizer and as second messenger of FSH in the ovaries, thus regulating glucose metabolism and supporting ovarian function. The presence of two inositol isomers, namely myo-inositol and D-chiro-inositol, in defined ratios in human tissues suggests that supplementation with both would be ideal. Despite numerous evidence available, the ratio that gives the best clinical results is still debated. In the present clinical trial, patients will be given a dietary supplement containing myo-inositol and D-chiro-inositol in two ratios (either 40:1 or 3.6:1, respectively) for three months. Restoration of regular menstrual cycle and of hormonal status will be the primary goal of the intervention.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTMyo-Inositol and D-Chiro-Inositol (40:1)Myo-inositol and D-chiro-inositol (40:1 ratio), 2 grams (twice a day) for three months
DIETARY_SUPPLEMENTMyo-Inositol and D-Chiro-Inositol (3.6:1)Myo-inositol and D-chiro-inositol (3.6:1 ratio), 1.4 grams (once daily) for three months

Timeline

Start date
2024-11-01
Primary completion
2025-03-06
Completion
2025-03-14
First posted
2024-12-04
Last updated
2025-04-08

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT06715527. Inclusion in this directory is not an endorsement.